A multicentre randomised phase III trial comparing atezolizumab plus bevacizumab and standard chemotherapy versus bevacizumab and standard chemotherapy as first-line treatment for advanced malignant pleural mesothelioma
BEAT-meso: Bevacizumab and atezolizumab in malignant pleural mesothelioma
Chemotherapy with cisplatin plus pemetrexed is the currently approved standard as first-line therapy for patients with malignant pleural mesothelioma. The best survival outcome to date has been achieved by combining standard chemotherapy with bevacizumab. However, new treatment strategies are needed in order to further improve outcome. Immunotherapy has achieved promising results in a subset of patients with PD-L1-positive tumours in the second-line setting.
The aim of the BEAT-meso trial was to address whether the addition of the anti-PD-L1 antibody atezolizumab given in combination with standard chemotherapy plus bevacizumab improves the outcome in advanced treatment-naïve malignant pleural mesothelioma patients.
Trial Scheme
